Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

91.35 +0.86 (+0.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
52 53 Next >
Gilead Sciences (GILD) Q3 2022 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Why Gilead Sciences Stock Is Rising After Hours
Gilead Sciences Inc (NASDAQ: GILD) shares are trading higher in Thursday's after-hours session after the company reported better-than-expected  
Via Benzinga
With A Breakout On The Line, Gilead Sciences Reports Massive Cancer Drug Sales
Gilead stock is approaching a buy point out of a saucer base. 
Via Investor's Business Daily
Gilead Sciences Announces Third Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities
From Gilead Sciences, Inc.
Via Business Wire
Gilead's Trodelvy Under FDA Review For Pre-Treated HR+/HER2- Metastatic Breast Cancer
Via Benzinga
The Top 5 Stocks Cathie Wood Bought and Sold This Week
Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.45% on an annualized basis producing an average annual return of 14.87%. Currently, Gilead Sciences has a market... 
Via Benzinga
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
From Gilead Sciences, Inc.
Via Business Wire
SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19
Reuters US Lawmakers Plan Hearing On Kroger, Albertsons' $25B Merger 
Via Benzinga
US Sends Gilead's COVID-19 Antiviral To Safeguard Health Workers In Uganda Ebola Outbreak
The U.S. sent Gilead Sciences Inc's (NASDAQ: GILD) remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda as a response to the Ebola outbreak. 
Via Benzinga
Europe Approves First CAR T-Cell Therapy For B-Cell Lymphoma In 30 Years to Improve Upon Standard of Care
Via Benzinga
Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022
From Gilead Sciences, Inc.
Via Business Wire
Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
MacroGenics Shares Jump On Gilead Licensing Pact For Blood Cancer Candidates
Via Benzinga
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
From Gilead Sciences, Inc.
Via Business Wire
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
All three of these medical stocks offer a high-yield dividend. 
Via The Motley Fool
Why Cash-Rich Companies And #ETFs Are Beating The Market?
Investors believe that “cash is king” in the current environment of surging inflation, rising rates, and a potential economic downturn. ETFs that hold cash-rich companies have seen a lot of interest... 
Via Talk Markets
Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022
From Gilead Sciences, Inc.
Via Business Wire
Halliburton To Jump Around 44%? This Analyst Slashes PT On Block By 26%
Morgan Stanley boosted the price target on Halliburton Company (NYSE: HAL) from $40 to $42. Halliburton shares rose 0.8% to close at $29.80 on Wednesday. 
Via Benzinga
Dividend Income Update September 2022
With the start of the final quarter of 2022, it’s time to take a look back at my previous month of dividend income. 
Via Talk Markets
Gilead Sciences Whale Trades Spotted
Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
These 2 Growth Stocks Have Potential Catalysts on the Way
Both drugmakers have been outperforming the market -- which may continue if they earn important regulatory approvals soon. 
Via The Motley Fool
Want to Collect 4% in Dividends Every Month? Buy These 3 Stocks
These stocks pay at different intervals and collectively can ensure you're collecting a dividend payment each month. 
Via The Motley Fool
4 Biotech Stocks With Huge Incoming Catalysts
All four of these drugmakers are expecting important FDA approval decisions over the next few months. 
Via The Motley Fool
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
How to Find Stocks That Rise 10x
Investors looking for 10X stocks should prioritize companies in high-growth areas that demonstrate high earnings quality. 
Via InvestorPlace
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing... 
Via FinancialNewsMedia
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,500 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.67% on an annualized basis producing an average annual return of 14.39%. Currently, Gilead Sciences has a market... 
Via Benzinga
A Bullish Sign Appears On Gilead Sciences's Chart
If history is any guide, there may be good fortune ahead for shares of Gilead Sciences (NASDAQ:GILD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for... 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.